{"id":3285,"date":"2025-10-06T05:52:40","date_gmt":"2025-10-06T05:52:40","guid":{"rendered":"https:\/\/genoks.com.tr\/docs\/genoxhere-brca-en\/"},"modified":"2026-05-01T21:43:15","modified_gmt":"2026-05-01T21:43:15","password":"","slug":"genoxhere-brca-en","status":"publish","type":"docs","link":"https:\/\/genoks.com.tr\/en\/docs\/genoxhere-brca-en\/","title":{"rendered":"What is the BRCA Gene? What does GenoXhere BRCA Cover?"},"content":{"rendered":"

<\/p>\n

What is the BRCA Gene? What does GenoXhere BRCA Cover?<\/strong><\/p>\n

BRCA1 and BRCA2 are tumor suppressor genes essential for DNA double-strand break repair via homologous recombination. Pathogenic germline variants in either gene markedly increase lifetime risk of breast (~55-72% BRCA1, ~45-69% BRCA2), ovarian (~39-44% BRCA1, ~11-17% BRCA2), prostate, pancreatic, and male breast cancers. The GenoXhere BRCA panel sequences both genes including large rearrangements (MLPA), reporting variants per ACMG\/AMP 2015 criteria.<\/p>\n

Who should be tested:<\/strong> personal\/family history of early-onset (\u226450 y) breast cancer, ovarian cancer at any age, male breast cancer, triple-negative breast cancer \u226460 y, Ashkenazi Jewish ancestry, and metastatic prostate or pancreatic cancer per NCCN guidelines. Clinical management for carriers includes annual breast MRI from age 25, mammography from 30, risk-reducing salpingo-oophorectomy by 35-40 (BRCA1) or 40-45 (BRCA2), and PARP inhibitor therapy in select cancers.<\/p>\n

<\/p>\n

BRCA Geni Nedir?<\/strong><\/p>\n

BRCA, meme kanseri ve yumurtal\u0131k kanseri gibi kanser t\u00fcrlerine yatk\u0131nl\u0131k olu\u015fturan genlerin ad\u0131d\u0131r. BRCA1 ve BRCA2 olarak bilinen iki farkl\u0131 gen, normalde kanserin \u00f6nlenmesine yard\u0131mc\u0131 olan DNA tamirinde g\u00f6revlidir.<\/p>\n

\"GenoXhere

GenoXhere BRCA<\/p><\/div>\n

Ancak, baz\u0131 insanlarda bu genlerde do\u011fal bir mutasyon meydana gelir ve bu ki\u015filer meme kanseri, yumurtal\u0131k kanseri ve di\u011fer kanser t\u00fcrlerine yakalanma riski ta\u015f\u0131rlar. Bu ki\u015filer, BRCA mutasyonlar\u0131ndan kaynaklanan kanser riskini azaltmak i\u00e7in \u00e7e\u015fitli \u00f6nleyici tedbirler alabilirler. BRCA mutasyonlar\u0131n\u0131n ke\u015ffi, ailelerde genetik ge\u00e7i\u015fli meme kanseri ve yumurtal\u0131k kanseri riskini belirlemeye yard\u0131mc\u0131 olabilir ve risk alt\u0131ndaki bireylerin erken te\u015fhis ve \u00f6nleyici tedbirler almas\u0131n\u0131 sa\u011flayabilir.<\/p>\n\n\n\n\n\n\n\n\n
Gen :<\/strong><\/td>\nBRCA1 | BRCA2<\/td>\n<\/tr>\n
Y\u00f6ntem :<\/strong><\/td>\nT\u00fcm Gen Dizi Analizi<\/td>\n<\/tr>\n
Raporlama S\u00fcresi :<\/strong><\/td>\n8 Hafta (+\/- 2 Hafta)<\/td>\n<\/tr>\n
Prenatal\/ Postnatal:<\/strong><\/strong><\/td>\nPostnatal<\/td>\n<\/tr>\n
Gerekli Numune<\/strong>:<\/td>\nEDTA’l\u0131 Kan (2-4 ml)<\/td>\n<\/tr>\n
Saklama \/ Ta\u015f\u0131ma S\u0131cakl\u0131\u011f\u0131:<\/strong><\/td>\n+ 4C\u00b0\/ + 24C\u00b0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

T\u00fcm genetik testlerimiz “Hasta Onam Formu”<\/strong> ve “KVKK Formu”<\/strong>nun imzalanmas\u0131n\u0131n ard\u0131ndan \u00e7al\u0131\u015f\u0131lmaya ba\u015flan\u0131r.<\/p>\n

\n

Detayl\u0131 Bilgi Almak \u0130\u00e7in Bize Mesaj Atabilirsiniz.<\/strong><\/p>\n\n\n\n
[contact-form-7 id=”710″ title=”genetik ba\u015fvuru”]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Genoks Genetik Hastal\u0131klar De\u011ferlendirme Merkezi T.C. Sa\u011fl\u0131k Bankanl\u0131\u011f\u0131nca denetlenen ve GHDM-SM\/06.15\/01 ruhsat numaras\u0131 ile hizmet veren sa\u011fl\u0131k kurulu\u015fudur. genoks.com.tr web sayfas\u0131nda bulunan bilgiler, genetik de\u011ferlendirme ve\/veya tan\u0131-te\u015fhis ama\u00e7l\u0131 kullan\u0131lmamal\u0131d\u0131r. T\u00fcm i\u00e7erikler bilgilendirme ama\u00e7l\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

What is the BRCA Gene? What does GenoXhere BRCA Cover? BRCA1 and BRCA2 are tumor suppressor genes essential for DNA double-strand break repair via homologous recombination. Pathogenic germline variants in either gene markedly increase lifetime risk of breast (~55-72% BRCA1, [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"doc_category":[204],"doc_tag":[92,105,106],"class_list":["post-3285","docs","type-docs","status-publish","hentry","doc_category-genoks-gdhm-genetic-tests","doc_tag-brca","doc_tag-kalitsal","doc_tag-kanser"],"aioseo_notices":[],"year_month":"2026-05","word_count":391,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"admin","author_nicename":"admin","author_url":"https:\/\/genoks.com.tr\/en\/author\/admin\/"},"doc_category_info":[{"term_name":"Genoks GDHM Genetic Tests","term_url":"https:\/\/genoks.com.tr\/en\/docs-category\/genoks-gdhm-genetic-tests\/"}],"doc_tag_info":[{"term_name":"BRCA","term_url":"https:\/\/genoks.com.tr\/docs-tag\/brca\/"},{"term_name":"Kal\u0131tsal","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kalitsal\/"},{"term_name":"kanser","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kanser\/"}],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t